Journal
CANCER CELL
Volume 27, Issue 1, Pages 97-108Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2014.11.007
Keywords
-
Categories
Funding
- NIH [R01CA137008]
- AIRC, Italy
- Novartis Pharmaceuticals
Ask authors/readers for more resources
BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (p110a), is currently in clinical trials for the treatment of solid tumors, especially luminal breast cancers with PIK3CA mutations and/or HER2 amplification. This study reveals that, even among these sensitive cancers, the initial efficacy of p110 alpha inhibition is mitigated by rapid re-accumulation of the PI3K product PIP3 produced by the p110 beta isoform. Importantly, the reactivation of PI3K mediated by p110b does not invariably restore AKT phosphorylation, demonstrating the limitations of using phospho-AKT as a surrogate to measure PI3K activation. Consistently, we show that the addition of the p110 beta inhibitor to BYL719 prevents the PIP3 rebound and induces greater antitumor efficacy in HER2-amplified and PIK3CA mutant cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available